Floatz logo

YTTRIUM (90 Y)

Disease Related To Solid Organ Transplantation

University Health Network, TorontoOtherPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Disease Related To Solid Organ Transplantation cohort.

Asset / SponsorPhaseRating
TACROLIMUS
The Second Hospital of Tangshan
Phase 4BBB
Giapreza
University of California, San Francisco
Phase 4BBB
Everolimus
Novartis Pharmaceuticals
Phase 3BB
Equine Atg
University Hospital, Toulouse
Phase 4BB
Semaglutide
University Health Network, Toronto
Phase 4BB

View all 34 →

Same molecule, other indications

YTTRIUM (90 Y) is also rated in:

hepatocellular carcinomaActive
B
Indicative · Phase 3
58 / 100
View asset →
metastatic neoplasmActive
CC
Indicative · Phase 1
43 / 100
View asset →
liver cancerActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →